Quick Answer
Ovid Therapeutics Inc. reported Operating Income of -$42.44 million for fiscal year 2025.
Ovid Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$42.44M | +31.4% |
| 2024 | -$61.88M | -4.4% |
| 2023 | -$59.28M | -6.7% |
| 2022 | -$55.55M | -144.7% |
| 2021 | $124.21M | +252.5% |
| 2020 | -$81.43M | -32.6% |
| 2019 | -$61.41M | -16.0% |
| 2018 | -$52.93M | +18.6% |
| 2017 | -$65.01M | -188.5% |
| 2016 | -$22.54M | -70.8% |
| 2015 | -$13.19M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$12.52M | +5.3% | -146.9% |
| June 30, 2025 | -$5.07M | +75.3% | +59.6% |
| March 31, 2025 | -$12.55M | +27.9% | +5.1% |
| September 30, 2024 | -$13.23M | -10.0% | +35.5% |
| June 30, 2024 | -$20.52M | -44.8% | -17.8% |
| March 31, 2024 | -$17.42M | -17.0% | -44.8% |
| September 30, 2023 | -$12.03M | +6.1% | +15.1% |
| June 30, 2023 | -$14.17M | +0.9% | +4.8% |
- Ovid Therapeutics Inc. showed an increase of +31.4% in Operating Income compared to the prior fiscal year.
- Over the 2015–2025 period, Ovid Therapeutics Inc.’s operating income has declined by 221.7% (from -$13.19 million to -$42.44 million).
- The most recent figure is from Ovid Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: